Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, expectations were $0.92. Operator: Good day, ladies and gentlemen, and ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits. NORTHAMPTON, MA / ACCESSWIRE / December 18, 2024 / Illumina How would it feel to know the ...

Illumina is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 The company ...

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation ...